Clinical Scorecard: FDA approves liquid cevimeline for Sjögren’s disease

At a Glance

Key Highlights

• FDA approved an oral solution formulation of cevimeline hydrochloride (Evoxac) for dry mouth in adults with Sjögren’s disease.
• The solution is an alternative formulation of an established medication, not a new active ingredient or indication.
• Approval relied in part on existing safety and efficacy data for cevimeline capsules; the announcement reported no new randomized efficacy trial or comparative effectiveness data.
• The source does not establish superior symptom relief with the liquid formulation.
• Cosette Pharmaceuticals expected US commercial availability by the end of 2026; concentration, dosing instructions, and price were not specified.

Guideline-Based Recommendations

Diagnosis

Management

• Cevimeline is indicated for symptomatic dry mouth associated with Sjögren’s disease, rather than treatment of the underlying autoimmune disease.
• The oral solution provides an alternative administration option for patients who have difficulty swallowing capsules.

Monitoring & Follow-up

• Review concomitant medications and monitor for cardiovascular, respiratory, and cholinergic adverse reactions.
• Advise patients experiencing increased sweating to maintain adequate hydration.

Risks

• Potential adverse effects include cardiac rhythm and heart rate disturbances, bronchoconstriction, increased respiratory secretions, visual disturbances, and cholinergic reactions such as excessive sweating, nausea, abdominal discomfort, dizziness, and diarrhea.
• Cevimeline is contraindicated in uncontrolled asthma, known hypersensitivity to the medication, and conditions in which pupillary constriction is undesirable, including acute iritis and narrow-angle glaucoma.
• Additional precautions apply to patients with cardiovascular disease, obstructive pulmonary conditions, or a history of kidney stones or gallstones.

Patient & Prescribing Data

Adults with Sjögren’s disease and dry mouth; the liquid formulation may be an option for those who have difficulty swallowing capsules.

The oral solution contains the established active ingredient cevimeline hydrochloride. The source provides no concentration, dosing instructions, or price and reports no evidence of superior symptom relief compared with capsules.

Clinical Best Practices

• Consider the oral solution as an alternative formulation for patients who have difficulty swallowing capsules.
• Review concomitant medications and monitor for cardiovascular, respiratory, and cholinergic adverse reactions.
• Account for the stated contraindications and precautions when considering treatment.
• Counsel patients experiencing increased sweating to maintain adequate hydration.

Related Resources & Content

• Cosette Pharmaceuticals press release